Frederick Haraka

In the News

Ifakara scientist explains why ending Tuberculosis requires better diagnostics

Ending tuberculosis through better diagnostics Author: Dr. Frederick Haraka, MD Yes, to end tuberculosis (TB), we need better diagnostic tools! TB is among the deadliest diseases in the world. In …

Study: 12% of people living with HIV in rural Tanzania have hypertension

Dar es Salaam, Tanzania (March 9, 2017). IHI Research Scientist Dr Kim Mwamelo presents findings of the study in Boston, US, last year at the Conference on Retroviruses and Opportunistic …

Recent Projects

Assessing the progress towards rabies elimination from Pemba Island, Tanzania

Rabies is a deadly disease endemic in dog populations across Africa. Although rabies can be eliminated through mass dog vaccination, there has been little investment in dog vaccination in Africa …

Engaging pastoralists in controlling malaria mosquitoes in their communities

The project is aimed at applying pastoralists’ knowledge to find water bodies during the dry season and accurately identify aquatic habitats that can be treated with larvicide pyriproxyfen (PPF) to …

Frederick Haraka

Research Scientist

Dr. Frederick Haraka is a research scientist at Ifakara Health Institute, working within the Tuberculosis research group. Prior to joining the institute in 2010, Dr. Haraka obtained his Medical Degree from the Muhimbili University of Health and Allied sciences, Tanzania, in 2009, and in 2013 received his Master’s degree in Applied Epidemiology from the University of Nottingham in the UK, with merit. He is currently registered as a PhD candidate in Epidemiology at the Swiss Tropical and Public Health institute, University of Basel in Switzerland. Dr. Haraka has experience in leading and implementing Good Clinical Practice (GCP), regulated clinical trials of Tuberculosis treatment regimen, vaccines and diagnostics. He is also actively involved in designing, implementing and analysing observational studies in TB and HIV. Following this interest, Dr. Haraka has numerous publications in both local and international journals focused around issues on TB and HIV. Dr. Haraka is currently a site Principal Investigator, leading a phase 2 multi-centre TB treatment regimen trial funded and sponsored by Global alliance for tuberculosis drug development, titled “A Phase 2 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug‐Sensitive or Multi Drug‐Resistant, Smear‐Positive Pulmonary Tuberculosis”. Beyond his scientific research, Dr Haraka is a part-time lecturer at International Medical and Technological University and Hubert Kairuki Memorial University, and mentor to junior researchers in the Institutes TB research group.

View Dr. Haraka’s Research Interests & Publications

Projects

Evaluation of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide for treatment of newly-diagnosed TB patients

Tanzania lung health study: prevalence and risk of chronic obstructive pulmonary disease

Evaluation of efficacy, safety and tolerability of a three-drug regimen (Moxifloxacin+PA‐824+Pyrazinamide) for TB and MDR-TB

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016